Stock Research for ACAD

Current Price


Latest Update: 2018-01-19 16:00:00

$ 26.9500
$ 26.9000
$ 26.9200

Featured Broker: TradeStation

Get the due diligence for another stock.


ACAD Stock Chart & Research Data

The ACAD chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ACAD chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


ACAD Due diligence Resources & Stock Charts

The ACAD stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ACAD Detailed Price Forecast - CNN Money CNN View ACAD Detailed Summary - Google Finance
Yahoo View ACAD Detailed Summary - Yahoo! Finance Zacks View ACAD Stock Research & Analysis -

Stock Analysis

TradeIdeas View ACAD Trends & Analysis - Trade-Ideas Barrons View ACAD Major Holders - Barrons
NASDAQ View ACAD Call Transcripts - NASDAQ Seeking View ACAD Breaking News & Analysis - Seeking Alpha
Spotlight View ACAD Annual Report - OTC Report View ACAD OTC Short Report -
TradeKing View ACAD Fundamentals - TradeKing Charts View ACAD SEC Filings - Bar Chart
WSJ View Historical Prices for ACAD - The WSJ Morningstar View Performance/Total Return for ACAD - Morningstar
MarketWatch View the Analyst Estimates for ACAD - MarketWatch CNBC View the Earnings History for ACAD - CNBC
StockMarketWatch View the ACAD Earnings - StockMarketWatch MacroAxis View ACAD Buy or Sell Recommendations - MacroAxis
Bullish View the ACAD Bullish Patterns - American Bulls Short Pains View ACAD Short Pain Metrics -

Social Media Mentions

StockTwits View ACAD Stock Mentions - StockTwits PennyStocks View ACAD Stock Mentions - PennyStockTweets
Twitter View ACAD Stock Mentions - Twitter Invest Hub View ACAD Investment Forum News - Investor Hub
Yahoo View ACAD Stock Mentions - Yahoo! Message Board Seeking Alpha View ACAD Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for ACAD - Insider Cow View Insider Transactions for ACAD - Insider Cow
CNBC View ACAD Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ACAD - OTC Markets
Yahoo View Insider Transactions for ACAD - Yahoo! Finance NASDAQ View Institutional Holdings for ACAD - NASDAQ

Stock Charts

FinViz View ACAD Stock Insight & Charts - StockCharts View ACAD Investment Charts -
BarChart View ACAD Stock Overview & Charts - BarChart Trading View View ACAD User Generated Charts - Trading View

Latest Financial News for ACAD

A Breakout in Aurinia Pharmaceuticals Inc May Be Imminent
Posted on Friday January 19, 2018

The downtrend in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) may end soon — not from the renewed interest in biotech stocks but because of Aurina’s upcoming revenue potential. Aurina has a potential blockbuster drug, called Voclosporin, that is in the clinical stages. AUPH’s priorities during both its second and third quarter were the Aurora Phase III trial.

See what the IHS Markit Score report has to say about ACADIA Pharmaceuticals Inc.
Posted on Friday January 12, 2018

ACADIA Pharmaceuticals Inc NASDAQ/NGS:ACAD

3 Keys for Acadia Pharmaceuticals to Succeed in 2018
Posted on Wednesday January 10, 2018

Acadia CEO Stephen Davis outlines the path to success for the biotech at the J.P. Morgan Healthcare Conference.

Today’s Research Reports on Stocks to Watch: ACADIA Pharmaceuticals Inc. and Exact Sciences Corporation
Posted on Tuesday January 09, 2018

NEW YORK, NY / ACCESSWIRE / January 9, 2018 / It was a day of losses for ACADIA on Monday, closing the day down a little over 6% at $27.11. There was no major news from the company whose stock was trading ...

ACADIA Pharmaceuticals (ACAD) & Beyondspring (BYSI) Financial Comparison
StockNewsTimes - 15 hours ago
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders.
Revenue Approximations Analysis: HCP, Inc. (HCP), ACADIA Pharmaceuticals Inc ... - StockNewsJournal
TD Asset Management Inc. Trims Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ ... - Dispatch Tribunal

ACADIA Pharmaceuticals: Due For A Rebound
Seeking Alpha - Jan 8, 2018
After topping over $40 a share in October, shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) fell towards yearly lows ahead of the third-quarter earnings results.
Pluristem Therapeutics (PSTI) versus ACADIA Pharmaceuticals (ACAD) Financial ... - The Lincolnian Online
Traders Purchase Large Volume of ACADIA Pharmaceuticals Put Options (ACAD) - StockNewsTimes

ACADIA Pharmaceuticals Inc. (ACAD) Moves Lower on Volume Spike for January 19 - Jan 19, 2018
ACADIA Pharmaceuticals Inc. (ACAD) traded on unusually high volume on Jan. 19, as the stock lost 3.1% to close at $26.92. On the day, ACADIA Pharmaceuticals Inc. saw 3.53 million shares trade hands on 15,669 trades. Considering that the stock averages ...
Comparing Amgen Inc. (AMGN) and ACADIA Pharmaceuticals Inc. (ACAD) - StockNewsGazette
ACADIA Pharmaceuticals Inc. (ACAD) Director Laura Brege Sells 25000 Shares - StockNewsTimes

Acadia Remains Significantly Undervalued
Seeking Alpha - Jan 6, 2018
Acadia's approved drug Nuplazid had a strong 2017. In Q3, Nuplazid sales totalled $35.6 million. Following another strong quarter, Acadia increased its full-year revenue guidance. The company is expecting Nuplazid net sales for 2017 to be between $124 ...

Enter a stock symbol to view the stock details.